using an ai model to quantify under-utilization of allosct for aml in the uk
Published 2 months ago • 48 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
8:05
using ai to segment and classify bone marrow cells in patients with aml
-
7:25
ai in hematology: advances, challenges, and future applications
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
3:39
applications of ai in hemonc: improving diagnosis & predicting outcomes and response to therapy
-
1:52
implementing ai in hematology and the challenges this will overcome
-
2:47
using artificial intelligence to estimate overall mortality and non-relapse mortality after allosct
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
3:23
the need to teach medical students about ai/ml & to bring ai/ml specialists into healthcare research
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
4:04
management of al amyloidosis: measurement modalities, transplantation & car-t
-
2:20
ebmt diagnostic criteria for tma post-allosct and the role of complement activation
-
4:39
aml & mds: mac or ric?
-
3:46
the impact of cytogenetic risk on outcomes of haploidentical transplantation in r/r aml
-
8:34
hct in mds: cell source and conditioning type
-
2:57
why do we need ai in the hematology clinic?
-
2:53
autohct in dlbcl in the car-t era
-
2:11
synergistic activity of alnuctamab and celmods in multiple myeloma preclinical models